Hospital
The DCH Healthcare Authority
The DCH Healthcare Authority was paid $16.03M by Medicaid between Jan 2018 and Dec 2024, across 147 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoTHE DCH HEALTHCARE AUTHORITY
TUSCALOOSA, AL 35401
TUSCALOOSA, AL 35401
33aNPI1841394418assigned 09/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.03M
24GClaims757,375
24DCodes billed147
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Alabama
Rank by total paid#4 of 77
Median peer was paid$1.13M
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 136,188 | $2.25M | |
| 2019 | 145,670 | $2.50M | |
| 2020 | 91,792 | $1.66M | |
| 2021 | 96,748 | $1.86M | |
| 2022 | 97,273 | $2.19M | |
| 2023 | 111,158 | $3.19M | |
| 2024incomplete | 78,546 | $2.39M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 90,616 | 85,369 | $3.39M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 49,607 | 46,416 | $3.12M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 13% | 19,827 | 18,690 | $2.04M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 7,548 | 7,009 | $1.77M |
| 80053 | Comprehensive metabolic panel | 3.6% | 61,655 | 53,945 | $577K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.0% | 63,303 | 54,795 | $477K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 13,233 | 11,408 | $355K |
| 11043 | 1.8% | 2,805 | 1,188 | $296K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.7% | 7,973 | 7,532 | $279K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.7% | 12,781 | 12,352 | $276K |
| D9420 | 1.6% | 1,000 | 966 | $255K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.6% | 12,740 | 10,948 | $254K |
135 more codes
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.3% | 14,546 | $205K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 17,101 | $174K |
| 81001 | 1.0% | 43,126 | $164K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 1,911 | $163K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,915 | $150K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 56,099 | $150K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 124 | $147K |
| 87631 | <1% | 1,453 | $108K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,710 | $105K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,820 | $100K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,289 | $77K |
| 87081 | <1% | 7,815 | $69K | |
| 62323 | <1% | 746 | $57K | |
| 81025 | <1% | 17,673 | $56K | |
| 87634 | <1% | 952 | $56K | |
| 88142 | <1% | 2,235 | $53K | |
| 84466 | <1% | 5,549 | $53K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,155 | $52K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 2,233 | $49K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,025 | $45K |
| 83690 | <1% | 6,493 | $43K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,277 | $42K |
| 82607 | <1% | 4,216 | $38K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 15 | $35K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 828 | $33K |
| 84484 | <1% | 3,777 | $33K | |
| 80306 | <1% | 2,740 | $33K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 725 | $32K |
| 82553 | <1% | 2,049 | $32K | |
| 82728 | <1% | 5,532 | $32K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 240 | $30K |
| 82746 | <1% | 4,183 | $28K | |
| 87807 | <1% | 2,006 | $23K | |
| 86592 | <1% | 3,832 | $23K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 694 | $22K |
| 83540 | <1% | 5,550 | $22K | |
| 82550 | <1% | 2,474 | $21K | |
| 83735 | <1% | 3,352 | $20K | |
| 82077 | <1% | 1,824 | $20K | |
| 80055 | <1% | 369 | $19K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 983 | $19K |
| 83970 | <1% | 313 | $16K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 631 | $16K |
| 85027 | <1% | 3,589 | $14K | |
| 85045 | <1% | 4,592 | $14K | |
| 59025 | Fetal non-stress test | <1% | 2,566 | $13K |
| 85610 | <1% | 3,335 | $12K | |
| 59020 | <1% | 261 | $12K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,666 | $10K |
| 0001A | <1% | 357 | $9K | |
| 86703 | <1% | 537 | $9K | |
| 86850 | <1% | 1,241 | $8K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,178 | $8K |
| 80061 | Lipid panel | <1% | 503 | $8K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,211 | $8K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,102 | $8K |
| 86803 | <1% | 380 | $8K | |
| 96367 | <1% | 475 | $7K | |
| 86762 | <1% | 286 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 539 | $7K |
| 87340 | <1% | 433 | $7K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 31,917 | $7K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $7K |
| 85730 | <1% | 3,291 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 433 | $6K |
| 95811 | <1% | 29 | $6K | |
| 83655 | <1% | 283 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 106 | $4K |
| G0378 | Hospital observation service, per hour | <1% | 73 | $3K |
| 84100 | <1% | 994 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 401 | $3K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 16 | $3K |
| 84702 | <1% | 262 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,660 | $3K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,105 | $3K |
| 95819 | <1% | 12 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,258 | $2K |
| 81003 | <1% | 1,032 | $2K | |
| 82150 | <1% | 421 | $2K | |
| 86900 | <1% | 690 | $2K | |
| 86901 | <1% | 691 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,824 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,761 | $2K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 109 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 9,800 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 29 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,553 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 28 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 854 | $2K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,330 | $1K |
| 86140 | <1% | 634 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,176 | $1K |
| 83880 | <1% | 27 | $978.60 | |
| 74022 | <1% | 40 | $860.99 | |
| 76801 | <1% | 34 | $806.30 | |
| 80050 | General health panel | <1% | 16 | $766.50 |
| 84439 | <1% | 87 | $756.75 | |
| 83021 | <1% | 12 | $585.84 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 27 | $497.81 |
| 84156 | <1% | 69 | $348.29 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 97 | $332.50 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 50 | $331.40 |
| 83020 | <1% | 12 | $300.84 | |
| 82570 | <1% | 32 | $230.62 | |
| 82803 | <1% | 12 | $228.24 | |
| 82105 | <1% | 14 | $227.07 | |
| 72100 | <1% | 12 | $219.23 | |
| 84481 | <1% | 14 | $171.70 | |
| 82378 | <1% | 15 | $161.52 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 2,072 | $155.87 |
| 83605 | <1% | 26 | $145.73 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 93 | $139.25 |
| 74018 | <1% | 12 | $136.08 | |
| 85660 | <1% | 12 | $85.08 | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 1,855 | $77.26 |
| 87210 | <1% | 12 | $66.55 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,215 | $60.88 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 18 | $50.64 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 53 | $40.39 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 12 | $34.72 |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,333 | $32.91 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 43 | $10.50 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,847 | $8.72 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,449 | $3.87 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 1,277 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 49 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 14 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 359 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 150 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 12 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 379 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 250 | $0.00 |
| 11046 | 0% | 509 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 36 | $0.00 |
| 94760 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHINDMAN, KERI (PATIENT ACCOUNTS DIRECTOR)
Parent organizationTHE DCH HEALTHCARE AUTHORITY
| Provider | Location | Paid |
|---|---|---|
| Fayette Medical Center | Fayette, AL | $902K |
| The DCH Health Care Authority | Tuscaloosa, AL | $182K |
| Fayette Medical Center | Fayette, AL | $102.19 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.